[15] Tang L, Zhong R, He X, et al. Evidence for the association between IgG-antimitochondrial antibody and biochemical response to ursodeoxycholic acid treatment in primary biliary cholangitis. J Gastroenterol Hepatol, 2017,...
［27］ZHANG RM, ZHANG T, WU JH, et al. Clinical effect of liver-soothing, cholagogic, spleen-strengthening, and blood-activating therapy combined with ursodeoxycholic acid in treatment of primary biliary cholangitis［J］. Fujian Med J, 2019, 41(2): 27-30.(in Chinese)张如棉, 章亭, 吴剑华...
[14] Hansen BE, Watkins E, Yang K, et al . Seladelpar treatment of patients with primary biliary cholangitis (PBC) for 2 years improves the GLOBE PBC score and predicts improved transplant-free survival. J HEPATOL. 2022;77(0168-8278):S322-3. ...
[14] Hansen BE, Watkins E, Yang K, et al . Seladelpar treatment of patients with primary biliary cholangitis (PBC) for 2 years improves the GLOBE PBC score and predicts improved transplant-free survival. J HEPATOL. 2022;77(0168-8278):S322-3. ...
[14] Hansen BE, Watkins E, Yang K, et al . Seladelpar treatment of patients with primary biliary cholangitis (PBC) for 2 years improves the GLOBE PBC score and predicts improved transplant-free survival. J HEPATOL. 2022;77(0168-8278):S322-3. ...
UDCA will probably be the first treatment your doctor suggests. It can do a lot of good if you start it early on. If your doctor prescribes it, you may have to take it every day for the rest of your life. It slows liver damage and may make it less likely that you’ll need a ...
[摘要]原发性胆汁性胆管炎(P B C)是一种以肝内小胆管非化脓性炎症为特征的器官特异性自身免疫性疾病㊂早期干预治疗对P B C患者的预后及生活质量提升都有极为重要的作用,但由于疾病本身临床表现的非典型性及各种肝内㊁肝外常见并发疾病的干扰,如何对P B C患者进行早期诊断仍是目前临床上亟待解决的问题㊂...
*Overall liver health includes (but is not limited to) disease progression, liver biochemical markers (biomarkers), fibrosis, and treatment response. Current PBC treatment not enough? Up to 50% of peopleliving with PBC are still uncontrolled, even on treatment. There may be more you can do. ...
[4] CARBONE M, SHARP S J, FLACK S, et al. The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis [J]. Hepatology, 2016, 63(3): 930-50.[5] DE VEER R C, HARMS M H, CORPECHOT C,...